vs
Alector, Inc.（ALEC）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是Alector, Inc.的1.4倍（$8.8M vs $6.2M），林德同比增速更快（8.2% vs -88.5%），林德自由现金流更多（$898.0K vs $-184.1M），过去两年Alector, Inc.的营收复合增速更高（-37.4% vs -96.7%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
ALEC vs LIN — 直观对比
营收规模更大
LIN
是对方的1.4倍
$6.2M
营收增速更快
LIN
高出96.7%
-88.5%
自由现金流更多
LIN
多$185.0M
$-184.1M
两年增速更快
ALEC
近两年复合增速
-96.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $8.8M |
| 净利润 | — | — |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | 27.8% |
| 净利率 | — | — |
| 营收同比 | -88.5% | 8.2% |
| 净利润同比 | -1696.9% | — |
| 每股收益（稀释后） | — | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECLIN
| Q1 26 | — | $8.8M | ||
| Q4 25 | $6.2M | $8.8B | ||
| Q3 25 | $3.3M | $8.6B | ||
| Q2 25 | $7.9M | $8.5B | ||
| Q1 25 | $3.7M | $8.1B | ||
| Q4 24 | $54.2M | $8.3B | ||
| Q3 24 | $15.3M | $8.4B | ||
| Q2 24 | $15.1M | $8.3B |
净利润ALECLIN
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $-34.7M | $1.9B | ||
| Q2 25 | $-30.5M | $1.8B | ||
| Q1 25 | $-40.5M | $1.7B | ||
| Q4 24 | $-2.1M | $1.7B | ||
| Q3 24 | $-42.2M | $1.6B | ||
| Q2 24 | $-38.7M | $1.7B |
毛利率ALECLIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率ALECLIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | — | 23.0% | ||
| Q3 25 | -1153.6% | 27.5% | ||
| Q2 25 | -433.6% | 27.7% | ||
| Q1 25 | -1216.5% | 26.9% | ||
| Q4 24 | -13.4% | 27.4% | ||
| Q3 24 | -315.7% | 25.0% | ||
| Q2 24 | -302.4% | 26.4% |
净利率ALECLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | -1063.4% | 22.4% | ||
| Q2 25 | -387.7% | 20.8% | ||
| Q1 25 | -1101.6% | 20.6% | ||
| Q4 24 | -3.8% | 20.8% | ||
| Q3 24 | -275.2% | 18.5% | ||
| Q2 24 | -256.4% | 20.1% |
每股收益（稀释后）ALECLIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | — | $3.28 | ||
| Q3 25 | $-0.34 | $4.09 | ||
| Q2 25 | $-0.30 | $3.73 | ||
| Q1 25 | $-0.41 | $3.51 | ||
| Q4 24 | $-0.02 | $3.61 | ||
| Q3 24 | $-0.43 | $3.22 | ||
| Q2 24 | $-0.40 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $4.0M |
| 总债务越低越好 | $10.0M | $24.7M |
| 股东权益账面价值 | $30.6M | $40.1M |
| 总资产 | $293.2M | $86.3M |
| 负债/权益比越低杠杆越低 | 0.33× | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资ALECLIN
| Q1 26 | — | $4.0M | ||
| Q4 25 | $256.0M | $5.1B | ||
| Q3 25 | $291.1M | $4.5B | ||
| Q2 25 | $307.3M | $4.8B | ||
| Q1 25 | $354.6M | $5.3B | ||
| Q4 24 | $413.4M | $4.8B | ||
| Q3 24 | $457.2M | $5.2B | ||
| Q2 24 | $503.3M | $4.6B |
总债务ALECLIN
| Q1 26 | — | $24.7M | ||
| Q4 25 | $10.0M | $20.7B | ||
| Q3 25 | — | $18.6B | ||
| Q2 25 | — | $19.7B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $10.0M | $15.3B | ||
| Q3 24 | — | $17.5B | ||
| Q2 24 | — | $16.9B |
股东权益ALECLIN
| Q1 26 | — | $40.1M | ||
| Q4 25 | $30.6M | $38.2B | ||
| Q3 25 | $57.7M | $38.6B | ||
| Q2 25 | $71.2M | $38.5B | ||
| Q1 25 | $94.6M | $38.0B | ||
| Q4 24 | $126.8M | $38.1B | ||
| Q3 24 | $118.9M | $39.2B | ||
| Q2 24 | $150.6M | $38.2B |
总资产ALECLIN
| Q1 26 | — | $86.3M | ||
| Q4 25 | $293.2M | $86.8B | ||
| Q3 25 | $335.3M | $86.0B | ||
| Q2 25 | $356.4M | $86.1B | ||
| Q1 25 | $408.3M | $82.7B | ||
| Q4 24 | $468.3M | $80.1B | ||
| Q3 24 | $516.0M | $82.5B | ||
| Q2 24 | $570.7M | $80.2B |
负债/权益比ALECLIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | 0.33× | 0.54× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | 0.08× | 0.40× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-184.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-184.1M | $898.0K |
| 自由现金流率自由现金流/营收 | -2951.3% | 10.2% |
| 资本支出强度资本支出/营收 | 0.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-326.5M | $4.2B |
8季度趋势，按日历期对齐
经营现金流ALECLIN
| Q1 26 | — | — | ||
| Q4 25 | $-184.0M | $3.0B | ||
| Q3 25 | $-32.5M | $2.9B | ||
| Q2 25 | $-49.0M | $2.2B | ||
| Q1 25 | $-60.8M | $2.2B | ||
| Q4 24 | $-55.0M | $2.8B | ||
| Q3 24 | $-50.7M | $2.7B | ||
| Q2 24 | $-62.8M | $1.9B |
自由现金流ALECLIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | $-184.1M | $1.6B | ||
| Q3 25 | $-32.5M | $1.7B | ||
| Q2 25 | $-49.1M | $954.0M | ||
| Q1 25 | $-60.8M | $891.0M | ||
| Q4 24 | $-55.2M | $1.6B | ||
| Q3 24 | $-50.9M | $1.7B | ||
| Q2 24 | $-63.1M | $796.0M |
自由现金流率ALECLIN
| Q1 26 | — | 10.2% | ||
| Q4 25 | -2951.3% | 17.9% | ||
| Q3 25 | -997.6% | 19.4% | ||
| Q2 25 | -623.0% | 11.2% | ||
| Q1 25 | -1655.0% | 11.0% | ||
| Q4 24 | -101.8% | 18.8% | ||
| Q3 24 | -332.1% | 19.9% | ||
| Q2 24 | -418.6% | 9.6% |
资本支出强度ALECLIN
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 16.6% | ||
| Q3 25 | 0.3% | 14.8% | ||
| Q2 25 | 0.1% | 14.8% | ||
| Q1 25 | 0.5% | 15.7% | ||
| Q4 24 | 0.3% | 15.1% | ||
| Q3 24 | 1.4% | 12.8% | ||
| Q2 24 | 2.2% | 13.7% |
现金转化率ALECLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
